You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Article metrics

Article menu

Download PDFPDF

Research Article
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019110
Jan 2020885
Feb 202018189
Mar 202013135
Apr 202014149
May 202028289
Jun 2020191913
Jul 202019197
Aug 2020191918
Sep 202025255
Oct 202026268
Nov 202021217
Dec 2020242415
Jan 2021262613
Feb 2021151523
Mar 2021272716
Apr 2021222212
May 2021131310
Jun 2021383813
Jul 2021343417
Aug 2021282813
Sep 2021282814
Oct 2021272724
Nov 2021242421
Dec 202131314
Jan 2022273114
Feb 202213135
Mar 2022323513
Apr 202229297
May 2022333412
Jun 2022404112
Jul 202234368
Aug 202238389
Sep 2022454514
Oct 2022373910
Nov 2022323419
Dec 202233338
Jan 2023373813
Feb 2023595910
Mar 202351538
Apr 20239106
May 202314148
Jun 202316166
Jul 202320209
Aug 202311115
Sep 202314149
Oct 202320204
Nov 202378787
Dec 202320120310
Jan 202491925
Feb 2024242412
Mar 2024343414
Total16201642547